These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
457 related articles for article (PubMed ID: 18425987)
1. The safety of rosuvastatin in comparison with other statins in over 25,000 statin users in the Saskatchewan Health Databases. García-Rodríguez LA; González-Pérez A; Stang MR; Wallander MA; Johansson S Pharmacoepidemiol Drug Saf; 2008 Oct; 17(10):953-61. PubMed ID: 18425987 [TBL] [Abstract][Full Text] [Related]
2. The safety of rosuvastatin in comparison with other statins in over 100,000 statin users in UK primary care. García-Rodríguez LA; Massó-González EL; Wallander MA; Johansson S Pharmacoepidemiol Drug Saf; 2008 Oct; 17(10):943-52. PubMed ID: 18425988 [TBL] [Abstract][Full Text] [Related]
3. Results from a rosuvastatin historical cohort study in more than 45,000 Dutch statin users, a PHARMO study. Goettsch WG; Heintjes EM; Kastelein JJ; Rabelink TJ; Johansson S; Herings RM Pharmacoepidemiol Drug Saf; 2006 Jul; 15(7):435-43. PubMed ID: 16761304 [TBL] [Abstract][Full Text] [Related]
4. The comparative safety of rosuvastatin: a retrospective matched cohort study in over 48,000 initiators of statin therapy. McAfee AT; Ming EE; Seeger JD; Quinn SG; Ng EW; Danielson JD; Cutone JA; Fox JC; Walker AM Pharmacoepidemiol Drug Saf; 2006 Jul; 15(7):444-53. PubMed ID: 16761308 [TBL] [Abstract][Full Text] [Related]
5. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice. Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658 [TBL] [Abstract][Full Text] [Related]
6. Safety of rosuvastatin: update on 16,876 rosuvastatin-treated patients in a multinational clinical trial program. Shepherd J; Vidt DG; Miller E; Harris S; Blasetto J Cardiology; 2007; 107(4):433-43. PubMed ID: 17363845 [TBL] [Abstract][Full Text] [Related]
7. Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia. Kostapanos MS; Milionis HJ; Elisaf MS Am J Cardiovasc Drugs; 2010; 10(1):11-28. PubMed ID: 20104931 [TBL] [Abstract][Full Text] [Related]
8. Use of multiple international healthcare databases for the detection of rare drug-associated outcomes: a pharmacoepidemiological programme comparing rosuvastatin with other marketed statins. García Rodríguez LA; Herings R; Johansson S Pharmacoepidemiol Drug Saf; 2010 Dec; 19(12):1218-24. PubMed ID: 20922707 [TBL] [Abstract][Full Text] [Related]
9. Titration patterns with rosuvastatin as compared with other statins in clinical practice: a retrospective observational cohort study using an electronic medical record database. Fox KM; Gandhi SK; Ohsfeldt RL; Blasetto JW; Davidson MH Clin Ther; 2007 Nov; 29(11):2385-94. PubMed ID: 18158079 [TBL] [Abstract][Full Text] [Related]
10. Comparison of incidences of cardiovascular events among new users of different statins: a retrospective observational cohort study. Heintjes EM; Penning-van Beest FJ; Johansson S; Stalenhoef AF; Herings RM Curr Med Res Opin; 2009 Nov; 25(11):2621-9. PubMed ID: 19743959 [TBL] [Abstract][Full Text] [Related]
11. Effectiveness of rosuvastatin compared to other statins for the prevention of cardiovascular events-a cohort study in 395 039 patients from clinical practice. Motsko SP; Russmann S; Ming EE; Singh VP; Vendiola RM; Jones JK Pharmacoepidemiol Drug Saf; 2009 Dec; 18(12):1214-22. PubMed ID: 19780020 [TBL] [Abstract][Full Text] [Related]
12. Rosuvastatin in older patients with systolic heart failure. Kjekshus J; Apetrei E; Barrios V; Böhm M; Cleland JG; Cornel JH; Dunselman P; Fonseca C; Goudev A; Grande P; Gullestad L; Hjalmarson A; Hradec J; Jánosi A; Kamenský G; Komajda M; Korewicki J; Kuusi T; Mach F; Mareev V; McMurray JJ; Ranjith N; Schaufelberger M; Vanhaecke J; van Veldhuisen DJ; Waagstein F; Wedel H; Wikstrand J; N Engl J Med; 2007 Nov; 357(22):2248-61. PubMed ID: 17984166 [TBL] [Abstract][Full Text] [Related]
17. Effectiveness and tolerability of every-other-day rosuvastatin dosing in patients with prior statin intolerance. Backes JM; Venero CV; Gibson CA; Ruisinger JF; Howard PA; Thompson PD; Moriarty PM Ann Pharmacother; 2008 Mar; 42(3):341-6. PubMed ID: 18285559 [TBL] [Abstract][Full Text] [Related]
18. The risk of myopathy associated with thiazolidinediones and statins in patients with type 2 diabetes: a nested case-control analysis. Koro CE; Sowell MO; Stender M; Qizilbash N Clin Ther; 2008 Mar; 30(3):535-42. PubMed ID: 18405791 [TBL] [Abstract][Full Text] [Related]
19. Does statin therapy initiation increase the risk for myopathy? An observational study of 32,225 diabetic and nondiabetic patients. Nichols GA; Koro CE Clin Ther; 2007 Aug; 29(8):1761-70. PubMed ID: 17919557 [TBL] [Abstract][Full Text] [Related]
20. The safety of rosuvastatin as used in common clinical practice: a postmarketing analysis. Alsheikh-Ali AA; Ambrose MS; Kuvin JT; Karas RH Circulation; 2005 Jun; 111(23):3051-7. PubMed ID: 15911706 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]